Madrigal Pharmaceuticals (YDO1) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

YDO1 Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Madrigal

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

YDO1 Stock 12 Month Forecast

Average Price Target

€596.85

▲(24.68% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is €596.85 with a high forecast of €835.58 and a low forecast of €471.64. The average price target represents a 24.68% change from the last price of €478.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"258":"€258","547":"€547","836":"€836","402.5":"€402.5","691.5":"€691.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":835.58298356,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€835.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":596.8545331953845,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€596.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":471.64403334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€471.64</span>\n  </div></div>","useHTML":true}}],"tickPositions":[258,402.5,547,691.5,836],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,430.4,461.56792181230765,492.73584362461537,523.9037654369231,555.0716872492308,586.2396090615384,617.4075308738461,648.5754526861538,679.7433744984615,710.9112963107692,742.0792181230769,773.2471399353847,804.4150617476923,{"y":835.58298356,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,430.4,443.2041948611834,456.0083897223668,468.81258458355023,481.6167794447337,494.4209743059171,507.22516916710055,520.0293640282839,532.8335588894674,545.6377537506509,558.4419486118343,571.2461434730177,584.0503383342011,{"y":596.8545331953845,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,430.4,433.57261794923073,436.74523589846154,439.9178538476923,443.09047179692305,446.26308974615387,449.4357076953846,452.6083256446154,455.78094359384613,458.95356154307694,462.1261794923077,465.29879744153845,468.47141539076927,{"y":471.64403334,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":259.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":375.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":383.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":361.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":495.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":413.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":454.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":440.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":413,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":468.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":430.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€835.58

Average Price Target€596.85

Lowest Price Target€471.64

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andy Chen

Wolfe Research

€525.5

Buy

9.78%

Upside

Upgraded

08/04/26

Madrigal upgraded to Outperform from Peer Perform at Wolfe ResearchMadrigal upgraded to Outperform from Peer Perform at Wolfe Research

Eliana Merle

Barclays

€837.32→€835.58

Buy

74.55%

Upside

Reiterated

08/03/26

Barclays Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

Unknown Analyst

B. Riley Securities

Not Ranked

B. Riley Securities

€581.95

Buy

21.57%

Upside

Initiated

07/31/26

Madrigal Pharmaceuticals (MDGL) Gets a Buy from B. Riley Securities

Srikripa Devarakonda

Truist Financial

€615.83

Buy

28.65%

Upside

Reiterated

07/31/26

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial

Andrew Fein

H.C. Wainwright

€538.53

Buy

12.50%

Upside

Reiterated

07/31/26

Madrigal Therapeutics: Rezdiffra’s Expanding MASH Opportunity Supports Reiterated Buy Rating and Unchanged $620 Price Target

Ritu Baral

TD Cowen

€559.37

Buy

16.85%

Upside

Reiterated

07/30/26

MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating

Jason Zemansky

Bank of America Securities

€480.33→€471.64

Hold

-1.47%

Downside

Reiterated

07/30/26

Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543

Edward Nash

Canaccord Genuity

€502.04→€509.86

Buy

6.51%

Upside

Reiterated

07/29/26

Canaccord Genuity Remains a Buy on Madrigal Pharmaceuticals (MDGL)

Sadia Rahman

Wells Fargo

€594.98

Buy

24.29%

Upside

Initiated

07/27/26

Madrigal Pharmaceuticals initiated with an Overweight at Wells FargoMadrigal Pharmaceuticals initiated with an Overweight at Wells Fargo

Ashwani Verma

UBS

€581.09

Buy

21.39%

Upside

Reiterated

07/21/26

Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS

Jonathan Wolleben

Citizens JMP

€640.15→€641.89

Buy

34.09%

Upside

Reiterated

07/17/26

Madrigal Pharmaceuticals price target raised to $739 from $737 at CitizensMadrigal Pharmaceuticals price target raised to $739 from $737 at Citizens

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€521.15

Buy

8.87%

Upside

Reiterated

06/30/26

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Jefferies

Yasmeen Rahimi

Piper Sandler

€781.73

Buy

63.30%

Upside

Reiterated

06/29/26

Piper Sandler Remains a Buy on Madrigal Pharmaceuticals (MDGL)

Michael DiFiore

Evercore ISI

€566.32→€563.71

Buy

17.76%

Upside

Reiterated

05/07/26

Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISIMadrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI

Kaveri Pohlman

Clear Street

€462.96→€590.64

Buy

23.38%

Upside

Reiterated

05/06/26

Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear StreetMadrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andy Chen

Wolfe Research

€525.5

Buy

9.78%

Upside

Upgraded

08/04/26

Madrigal upgraded to Outperform from Peer Perform at Wolfe ResearchMadrigal upgraded to Outperform from Peer Perform at Wolfe Research

Eliana Merle

Barclays

€837.32→€835.58

Buy

74.55%

Upside

Reiterated

08/03/26

Barclays Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

Unknown Analyst

B. Riley Securities

Not Ranked

B. Riley Securities

€581.95

Buy

21.57%

Upside

Initiated

07/31/26

Madrigal Pharmaceuticals (MDGL) Gets a Buy from B. Riley Securities

Srikripa Devarakonda

Truist Financial

€615.83

Buy

28.65%

Upside

Reiterated

07/31/26

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial

Andrew Fein

H.C. Wainwright

€538.53

Buy

12.50%

Upside

Reiterated

07/31/26

Madrigal Therapeutics: Rezdiffra’s Expanding MASH Opportunity Supports Reiterated Buy Rating and Unchanged $620 Price Target

Ritu Baral

TD Cowen

€559.37

Buy

16.85%

Upside

Reiterated

07/30/26

MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating

Jason Zemansky

Bank of America Securities

€480.33→€471.64

Hold

-1.47%

Downside

Reiterated

07/30/26

Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543

Edward Nash

Canaccord Genuity

€502.04→€509.86

Buy

6.51%

Upside

Reiterated

07/29/26

Canaccord Genuity Remains a Buy on Madrigal Pharmaceuticals (MDGL)

Sadia Rahman

Wells Fargo

€594.98

Buy

24.29%

Upside

Initiated

07/27/26

Madrigal Pharmaceuticals initiated with an Overweight at Wells FargoMadrigal Pharmaceuticals initiated with an Overweight at Wells Fargo

Ashwani Verma

UBS

€581.09

Buy

21.39%

Upside

Reiterated

07/21/26

Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS

Jonathan Wolleben

Citizens JMP

€640.15→€641.89

Buy

34.09%

Upside

Reiterated

07/17/26

Madrigal Pharmaceuticals price target raised to $739 from $737 at CitizensMadrigal Pharmaceuticals price target raised to $739 from $737 at Citizens

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€521.15

Buy

8.87%

Upside

Reiterated

06/30/26

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Jefferies

Yasmeen Rahimi

Piper Sandler

€781.73

Buy

63.30%

Upside

Reiterated

06/29/26

Piper Sandler Remains a Buy on Madrigal Pharmaceuticals (MDGL)

Michael DiFiore

Evercore ISI

€566.32→€563.71

Buy

17.76%

Upside

Reiterated

05/07/26

Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISIMadrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI

Kaveri Pohlman

Clear Street

€462.96→€590.64

Buy

23.38%

Upside

Reiterated

05/06/26

Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear StreetMadrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Madrigal Pharmaceuticals

3 Months

Akash TewariJefferies

Success Rate

11/15 ratings generated profit

Average Return

+31.49%

Copying Akash Tewari's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +31.49% per trade.

1 Year

Thomas SmithLeerink Partners

Success Rate

17/21 ratings generated profit

Average Return

+52.30%

Copying Thomas Smith's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +52.30% per trade.

2 Years

Akash TewariJefferies

Success Rate

15/15 ratings generated profit

Average Return

+133.17%

Copying Akash Tewari's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +133.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

YDO1 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, YDO1 has received 16 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. YDO1 average Analyst price target in the past 3 months is 596.85.

Each month's total comprises the sum of three months' worth of ratings.

YDO1 Financial Forecast

YDO1 Earnings Forecast

Next quarter’s earnings estimate for YDO1 is -€0.75 with a range of -€1.73 to -€0.09. The previous quarter’s EPS was -€1.73. YDO1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.

YDO1 Sales Forecast

Next quarter’s sales forecast for YDO1 is €350.57M with a range of €333.67M to €368.62M. The previous quarter’s sales results were €315.93M. YDO1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.

YDO1 Stock Forecast FAQ

What is DE:YDO1’s average 12-month price target, according to analysts?

Based on analyst ratings, Madrigal’s 12-month average price target is 596.85.

What is DE:YDO1’s upside potential, based on the analysts’ average price target?

Madrigal has 24.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Madrigal a Buy, Sell or Hold?

Madrigal has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Madrigal’s share price target?

The average share price target for Madrigal is 596.85. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €835.58 ,and the lowest forecast is €471.64. The average share price target represents 24.68% Increase from the current price of €478.7.

What do analysts say about Madrigal?

Madrigal’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Madrigal?

To buy shares of DE:YDO1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Madrigal Pharmaceuticals (YDO1) Stock Forecast & Price Target

YDO1 Analyst Ratings

YDO1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Madrigal Pharmaceuticals

YDO1 Analyst Recommendation Trends

YDO1 Financial Forecast

YDO1 Earnings Forecast

YDO1 Sales Forecast

YDO1 Stock Forecast FAQ

Detailed List of Analyst Forecasts